CardioDx Sets Price Range on Planned IPO | GenomeWeb

NEW YORK (GenomeWeb News) – CardioDx today set the price range on its planned initial public offering and raised the maximum proposed aggregate offering price to $92.0 million.

In its amended Form S-1 filed with the US Securities and Exchange Commission, the Palo Alto, Calif.-based cardiovascular molecular diagnostics firm said it anticipates offering 5 million shares of its common stock at between $14 and $16 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.